JP2020504628A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504628A5
JP2020504628A5 JP2019556411A JP2019556411A JP2020504628A5 JP 2020504628 A5 JP2020504628 A5 JP 2020504628A5 JP 2019556411 A JP2019556411 A JP 2019556411A JP 2019556411 A JP2019556411 A JP 2019556411A JP 2020504628 A5 JP2020504628 A5 JP 2020504628A5
Authority
JP
Japan
Prior art keywords
sequence
amino acid
chain
cancer
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504628A (ja
JP7221213B2 (ja
Filing date
Publication date
Priority claimed from CN201611246592.0A external-priority patent/CN108250302A/zh
Application filed filed Critical
Publication of JP2020504628A publication Critical patent/JP2020504628A/ja
Publication of JP2020504628A5 publication Critical patent/JP2020504628A5/ja
Application granted granted Critical
Publication of JP7221213B2 publication Critical patent/JP7221213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556411A 2016-12-29 2017-12-27 多官能性タンパク質 Active JP7221213B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611246592.0 2016-12-29
CN201611246592.0A CN108250302A (zh) 2016-12-29 2016-12-29 一种多功能蛋白质
PCT/CN2017/118984 WO2018121605A1 (zh) 2016-12-29 2017-12-27 一种多功能蛋白质

Publications (3)

Publication Number Publication Date
JP2020504628A JP2020504628A (ja) 2020-02-13
JP2020504628A5 true JP2020504628A5 (enExample) 2021-07-26
JP7221213B2 JP7221213B2 (ja) 2023-02-13

Family

ID=62710858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556411A Active JP7221213B2 (ja) 2016-12-29 2017-12-27 多官能性タンパク質

Country Status (5)

Country Link
US (1) US11530264B2 (enExample)
EP (1) EP3578570A4 (enExample)
JP (1) JP7221213B2 (enExample)
CN (2) CN108250302A (enExample)
WO (1) WO2018121605A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016018100A2 (pt) 2014-02-07 2018-02-20 Univ Mcmaster acoplador antigênico de células t trifuncional, métodos e usos do mesmo
CN111479925B (zh) 2017-10-12 2024-03-08 麦克马斯特大学 具有y182t突变的t细胞-抗原偶联物及其方法和用途
JP7404279B2 (ja) * 2018-07-17 2023-12-25 トリウムビラ イミュノロジクス ユーエスエー,インク. 様々な構築物最適化を備えたt細胞抗原カプラ
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
CN110862967A (zh) * 2018-08-27 2020-03-06 天津天锐生物科技有限公司 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk
KR20210091714A (ko) * 2018-10-17 2021-07-22 이뮤놈 인코포레이티드 엑소좀-표적 이중 특이적 항체
WO2020165374A1 (en) * 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US20220112258A1 (en) * 2019-07-25 2022-04-14 I-Mab Biopharma Us Limited Bifunctional molecules with il-7 activity
CN113321738A (zh) * 2020-02-27 2021-08-31 启愈生物技术(上海)有限公司 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用
CN112110988A (zh) * 2020-08-21 2020-12-22 温州医科大学 一种具有毛发生长作用的多肽类似物及制备方法和应用
AU2022283819A1 (en) 2021-06-01 2024-01-04 Triumvira Immunologics Usa, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
CN116102655A (zh) * 2021-08-19 2023-05-12 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
JP2024534982A (ja) * 2021-09-09 2024-09-26 クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド 抗原ターゲティング、抗cd16aおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
WO2025096770A1 (en) * 2023-10-31 2025-05-08 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
CA2410551A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
CA2607954A1 (en) * 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
CN101743249B (zh) 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
CN101830986A (zh) * 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
CN101550191B (zh) * 2009-05-15 2011-08-24 无锡胜博生物技术有限公司 一种恶性黑素瘤t细胞纳米抗体、其编码序列及应用
JP5764127B2 (ja) * 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
US8507222B2 (en) * 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
AU2012245116A1 (en) * 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CN102559696A (zh) * 2011-09-26 2012-07-11 无锡赛特基因生物科技有限公司 一种重组人白细胞介素-15的高效可溶性表达方法
CN202239821U (zh) * 2011-09-27 2012-05-30 上海宏功机械科技有限公司 偏心强力反刮锪组合刀具
PL3489254T3 (pl) * 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2970985A1 (en) * 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
RU2689717C2 (ru) * 2014-01-08 2019-05-28 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Гетеродимерный белок il-15 и его применения

Similar Documents

Publication Publication Date Title
JP2020504628A5 (enExample)
JP2020515282A5 (enExample)
JP2020508663A5 (enExample)
JP7267321B2 (ja) 改善された特異性を有する改変型tリンパ球
US11530264B2 (en) Multifunctional protein
US11629335B2 (en) Methods of improving vector transduction efficiency into T lymphocytes
Chen et al. Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors
US11806365B2 (en) Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis
EP3575325A1 (en) Multi-target chimeric antigen receptor
JP2022515194A5 (enExample)
JP2018518978A5 (enExample)
AU2013204923A1 (en) Modified t lymphocytes having improved specificity
JP2023532080A5 (enExample)
EP4680729A1 (en) Methods of culturing v delta 1 t cells
AU2017204617B2 (en) Chimeric antigen receptors
CN106478823B (zh) Her1靶向性的嵌合抗原受体和nkt细胞及其制法和应用
Liu et al. IGHV4-34 B-cell receptor immunoglobulins from CLL stereotyped subset 4 react with influenza a virus: requirement for IGHV-DJ/Iglv-j rearrangement and isotype switching to IgG
Atherton et al. Abstract B096: Oncolytic vaccination for HPV induced cancer
HK1234782A1 (en) Methods of improving vector transduction efficiency into t lymphocytes
HK1234782B (en) Methods of improving vector transduction efficiency into t lymphocytes
NZ712373B2 (en) Modified t lymphocytes
HK1218049B (en) Modified t lymphocytes having improved specificity